Accordingly, in this phase 3 biomarker development and proof-of-concept study, we investigated whether urine YKL-40 on the day of AKI diagnosis from any cause can help predict outcome in hospitalized patients. The gene discussed is CHI3L1; the disease is acute kidney injury.